2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5921 Polyantigenic dendritic-cell vaccination against relapsed or refractory EBV-associated lymphoproliferative disorders:Results from a phase I clinical study

Chunrui Li, MD,PhD, Di Wang, MD, PhD2, Atsuhiko Hasegawa3, Huining Liu4, Peiling Zhang5, Yuhan Bao, MBBS6, Ning An7, Mei Huang8, Yi Xiao9, Donghua Zhang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology10, Miao Zheng11, Wei Huang12, Lijun Jiang13
1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Tumor Cell Biology, Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
4 KOUSAI Bio Co., Ltd.,, Shanghai, Shanghai, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background: Epstein-Barr virus (EBV) is a highly prevalent human herpesvirus and was the first human tumor associated virus to be discovered. Dendritic cell has become an ideal target for vaccine research due to its powerful antigen presentation capabilities. KSD-101 is an autologous dendritic cell (DC) vaccine loaded with EBV related antigen, designed to treat EBV-associated lymphoproliferative disorders (EBV-LPDs).

Aims: The primary endpoint was safety and tolerability, assessed by the incidence, nature and severity of treatment-related adverse events (TRAEs) and dose-limiting toxicities (DLTs). Secondary endpoint was to explore clinical and immune responses.

Methods: Eligible patients were aged 18-70 years with histologically or clinically confirmed relapsed/refractory EBV-LPDs. KSD-101 was administered subcutaneously on a schedule of approximately 2-week intervals for 3-5 doses. Dose escalation followed a standard 3 + 3 design. 

Results: Between January 16, 2023 and May 30, 2024, 19 patients (pts) were screened and 14 were enrolled and received at least one dose of KSD-101. Dose escalation evaluated 5.0 × 106 DCs per dose (n = 3) and 7.5 × 106 DCs per dose (n = 2). Based on cumulative safety, manufacturing feasibility and immunologic activity, 5.0 × 106 DCs per dose was selected as the biologically active recommended dose for expansion. In total, 12 pts received 5.0 × 106 DCs and 2 received 7.5 × 106 DCs per dose. KSD-101 was well tolerated at both dose levels, with no DLTs and no grade ≥3 TRAEs. The most frequent TRAEs were injection-site reactions (12/14, 85.7%) and transient fever (9/14, 64.3%), typically occurring within 24 hours of vaccination and resolving after a median of 10 and 3 days, respectively. Data cut-off was September 30, 2025, the median follow-up was 81.7 weeks (range, 7.7-130 weeks), and median overall survival (OS) and progression-free survival (PFS) had not been reached. Two hemophagocytic lymphohistiocytosis pts discontinued from the study due to rapid early-stage disease progression and subsequently received alternative therapeutic interventions. The objective response rate (ORR) was 91.7% (11/12) and the disease control rate (DCR) was 100.0% (12/12). Lymphocytes play a central role in immune system. In pts’ blood, an early increase in CD4? T cells and CD8? T cells by week 4 and B cells by week 6 after vaccinations was observed. At week 6, the regulatory T cells reached a nadir. To better characterize the EBV LMP2-specific CTLs, we evaluated the proportion of specific CTLs using peptide-MHC-tetramers. After infusion, EBV LMP2–specific CD8? T cells rose rapidly at week 6 and the peak proportion of EBV LMP2–specific CD8+ T cells in each pt (average, 3.58%) was significantly increased (p < 0.05) compared to baseline (average, 0.69%). 

Conclusion: As of now, KSD-101 has demonstrated good safety and efficacy and could activate immune system. Our study highlights its potential as a promising therapeutic agent for the treatment of EBV-LPDs. Larger prospective studies and a longer follow-up period are needed. Clinical trial information: NCT05635591.
Chunrui Li, MD,PhD: No relevant conflicts of interest to declare.